Side effects of psoriasis biologics commonly include mild to moderate upper respiratory tract infections. Biologics have brought new options to the treatment of psoriasis, and their effectiveness in clinical application has been widely demonstrated. Biological agents now used in clinical practice include tumor necrosis factor-alpha inhibitors, interleukin-17 & interleukin-23 (IL-23) inhibitors, and others. Among them, skuticilumab, an interleukin-17 inhibitor that selectively binds interleukin-17A, has shown good efficacy in the treatment of moderate-to-severe psoriasis. One case of multiple freckle-like nevi has been identified to date during the use of scuccizumab, which may be related to post-inflammatory hyperpigmentation. The most common adverse reaction during use is upper respiratory tract infection. However, the incidence of serious infections was low, and the incidence of malignant tumors and cardiovascular adverse events was ≤1%. No opportunistic infections, Candida infections, demyelinating diseases, new or worsening inflammatory bowel disease, or suicides have been reported.